Some studies have indicated that the presence of CD133+ cells correlates with glioblastoma malignancy and affects clinical outcome in glioma patients [10,78], suggesting that CD133+ GSC may play a major role in radio-chemoresistance and tumor aggressiveness. The gene discussed is PROM1; the disease is central nervous system cancer.